Introduction: To evaluate the role of single dose of intravitreal recombinant tissue plasminogen activator (RTPA) in patients with vitreomacular traction (VMT) and macular edema. Methodology: Eighteen eyes of 18 patients with VMT and macular edema, as evidenced by spectral domain optical coherence tomography (SD-OCT), were selected in our Malda Medical College. After proper history taking and required systemic examinations, each patient underwent detailed ophthalmic examination, including best corrected visual acuity (BCVA), intraocular pressure, slit lamp examination, fundal evaluation by indirect ophthalmoscopy, 78D, 90D lens. All patients underwent SD-OCT examination to evaluate central macular thickness (CMT). Then, after proper informed consent, intravitreal injections with 50 micrograms of RTPA were administered to each patient and all baseline examinations were repeated one month and three months after injection. Results:Postoperatively, 16 patients had complete posterior vitreous detachment (PVD) and 14 resolution of VMT. All participants showed an improvement in BCVA and reduction in CMT. Conclusion:Intravitreal RTPA might be a useful agent in resolution of VMT associated with macular edema.